Short answer
Regeneron Pharmaceuticals (REGN) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $5.1B (up 36.3% year over year) with net income of $1.9B.
Q3 2026 key financials · XBRL
- Revenue
- $5.1B
- +36.3% YoY · +19.2% QoQ
- Net income
- $1.9B
- +33.5% YoY · +50.3% QoQ
- Operating margin
- 40.0%
- EPS (diluted)
- $18.42
- +35.5% YoY · +51.0% QoQ
Source: XBRL data from the Regeneron Pharmaceuticals (REGN) Q3 2026 10-Q on SEC EDGAR. USD.
Regeneron Pharmaceuticals Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $5,115.8M, up $1,361.5M YoY from $3,754.3M
- Net income $1,948.7M vs $1,460.0M; operating margin 40.0% vs 27.3% YoY
- Best product line: Dupixent sales $6,540.5M globally; worst: EYLEA sales $658.4M, down 49% YoY
- Cash $3,659.1M, up $541.0M from December; operating cash flow $3,675.3M, down $132.9M
- Outlook: 2026 capital expenditures $1.050B to $1.100B; EYLEA headwinds from competition and patient transition to EYLEA HD
Risk Factors
- New U.S. Government Agreements triggered by May 2025 executive order: Most-Favored-Nation pricing and Medicaid product commitments may reduce reimbursement
- EYLEA HD patent risk heightened by USPTO post-grant review instituted March 2026 for U.S. Patent No. 12,168,036
- Limerick manufacturing interruption during Q1 and Q2 2026 disrupted bulk production following unanticipated facility repairs
- EYLEA U.S. net sales declined 41% year over year amid biosimilar competition and other pressures
- Distributor concentration: two customers represented 77% of total gross product revenue for nine months ended September 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Regeneron Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.